Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

被引：0
|
作者：
Flaherty, Lawrence E.
Moon, James
Atkins, Michael B.
Tuthill, Ralph
Thompson, John A.
Vetto, John T.
Haluska, Frank G.
Pappo, Alberto S.
Sosman, Jeffrey Alan
Redman, Bruce G.
Ribas, Antoni
Kirkwood, John M.
Sondak, Vernon K.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] ARIAD Pharmaceut, Cambridge, MA USA
[8] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Univ Michigan, Ann Arbor, MI 48109 USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[13] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Toxicity of adjuvant treatment with high-dose interferon alpha 2b (HD-IFN) in high-risk stage III melanoma patients (pts): The Italian experience.
    Romanini, A
    Sarti, S
    Murr, R
    Doria, S
    Rondini, M
    Orlandini, C
    Menichetti, T
    Pigozzo, J
    Chiarion-Sileni, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 727S - 727S
  • [22] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    Investigational New Drugs, 2020, 38 : 1334 - 1341
  • [23] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Li, Tao
    Jia, Dong-Dong
    Teng, Li-Song
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341
  • [24] Immunomodulatory effects of high-dose and lowdose interferon α2b in patients with high-risk resected melanoma -: The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690
    Kirkwood, JM
    Richards, T
    Zarour, HM
    Sosman, J
    Ernstoff, M
    Whiteside, TL
    Ibrahim, J
    Blum, R
    Wieand, S
    Mascari, R
    CANCER, 2002, 95 (05) : 1101 - 1112
  • [25] SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)
    Yao, James C.
    Guthrie, Katherine
    Moran, Cesar
    Strosberg, Jonathan R.
    Kulke, Matthew H.
    Chan, Jennifer A.
    LoConte, Noelle K.
    McWilliams, Robert R.
    Wolin, Edward M.
    Mattar, Bassam Ibrahim
    McDonough, Shannon
    Chen, Helen X.
    Blanke, Charles David
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
    Kim, Kevin B.
    Legha, Sewa S.
    Gonzalez, Rene
    Anderson, Clay M.
    Johnson, Marcella M.
    Liu, Ping
    Papadopoulos, Nicholas E.
    Eton, Omar
    Plager, Carl
    Buzaid, Antonio C.
    Prieto, Victor G.
    Hwu, Wen-Jen
    Frost, Angela M.
    Alvarado, Gladys
    Hwu, Patrick
    Ross, Merrick I.
    Gershenwald, Jeffrey E.
    Lee, Jeffrey E.
    Mansfield, Paul F.
    Benjamin, Robert S.
    Bedikian, Agop Y.
    MELANOMA RESEARCH, 2009, 19 (01) : 42 - 49
  • [27] SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha-2b Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (NCT00569127)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 15 - 16
  • [28] Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
    Yao, James C.
    Guthrie, Katherine A.
    Moran, Cesar
    Strosberg, Jonathan R.
    Kulke, Matthew H.
    Chan, Jennifer A.
    LoConte, Noelle
    McWilliams, Robert R.
    Wolin, Edward M.
    Mattar, Bassam
    McDonough, Shannon
    Chen, Helen
    Blanke, Charles D.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1695 - +
  • [29] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
    Laurie E. McLouth
    Yue Zheng
    Stephanie Smith
    F. Stephen Hodi
    Uma N. Rao
    Gary I. Cohen
    Thomas T. Amatruda
    Shaker R. Dakhil
    Brendan D. Curti
    Ibrahim Nakhoul
    Sreenivasa R. Chandana
    Charles L. Bane
    David E. Marinier
    Sandra J. Lee
    Vernon K. Sondak
    John M. Kirkwood
    Ahmad A. Tarhini
    Lynne I. Wagner
    Quality of Life Research, 2023, 32 : 183 - 196
  • [30] A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (US Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary I.
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345